Alyeska Investment Group
WINT

Alyeska Investment Group’s Windtree Therapeutics WINT Stock Holding History

Alyeska Investment Group’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-11
Closed -$3.51M – 596
2020
Q2 		$3.51M Buy
+11
New +$3.49M 0.05% 300

Other funds holding WINT

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Alyeska Investment Group's WINT Position: Q1 2024 in Review

Alyeska Investment Group sold out of Windtree Therapeutics (WINT) in Q1 2024, closing a stake of 152 shares — an estimated $98.2K sold.

Alyeska Investment Group first reported a position in WINT in Q3 2023 and held it in 2 quarters. The position peaked at $130K in Q3 2023. 4 funds tracked by Wall St. Rank hold WINT as of Q1 2024.

  • Alyeska Investment Group reported no remaining Windtree Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 152 Windtree Therapeutics shares in Q1 2024, an estimated $98.2K.
  • Alyeska Investment Group first reported a position in Windtree Therapeutics in Q3 2023 and held it in 2 quarters.
  • Alyeska Investment Group's Windtree Therapeutics position peaked at $130K in Q3 2023.
  • 4 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2024.

Based on Alyeska Investment Group's 13F filing for Q1 2024, filed 15 May 2024.